InvestorsHub Logo
Followers 261
Posts 19732
Boards Moderated 0
Alias Born 10/03/2004

Re: scottsmith post# 206929

Friday, 12/08/2017 11:49:04 AM

Friday, December 08, 2017 11:49:04 AM

Post# of 403225
What I see is every indication for successful outcomes, all outcomes! Please point to any signal for possible failure:

“Cellceutix is encouraged by the interim data from the OM trial (a double blind, placebo controlled study), given the fact that there are no FDA-approved drugs for the prevention of OM in the study population. According to the preliminary interim results from the trial, only 2 of 9 patients (22.2%) on Brilacidin-OM therapy developed severe OM, defined as Grade 3 or Grade 4 on the World Health Organization (WHO) OM Grading Scale. Patients in the placebo-treated control arm developed severe OM at a much higher rate, with 7 of 10 patients (70%) progressing to that condition. There are now an additional 11 patients active in the trial and more are added weekly.”

Merry Spongebob Christmas and Seasons Greetings

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News